Publication Index-1

Changes in Methadone Treatment Practices: Results From a National Panel
Study, 1988-2000

by Thomas D’Aunno, PhD; Harold A. Pollack, PhD

Journal of the American Medical Association Vol. 288, No. 7 August 21, 2002

Context Results from several studies conducted in the early 1990s
showed that the majority of US methadone maintenance programs did not
use treatment practices that met established standards for the care of
heroin users. Effective treatment for heroin users is critical given the
upsurge in heroin use and the continued role of injection drug use in
the human immunodeficiency virus and hepatitis C epidemics.

Objectives To examine the extent to which US methadone maintenance
treatment programs have made changes in the past 12 years to provide
adequate methadone doses and to identify factors associated with
variation in program performance.

Design, Setting, and Participants Program directors and clinical
supervisors of nationally representative methadone treatment programs
that varied by ownership (for-profit, public, or private not-for-profit)
and setting (eg, free-standing, hospital-based) were surveyed in 1988 (n
= 172), 1990 (n = 140), 1995 (n = 116), and 2000 (n = 150).

Main Outcome Measures Percentage of patients in each treatment program
receiving methadone dosages of less than 40, 60, and 80 mg/d.

Results The percentage of patients receiving methadone dosage levels
less than the recommended 60 mg/d has decreased from 79.5% in 1988 to
35.5% in 2000. Results also show that programs with a greater percentage
of African American patients are especially likely to dispense low
dosages, while programs with Joint Commission on Accreditation of
Healthcare Organizations accreditation are more likely to provide
adequate methadone doses.

Conclusions Efforts to improve methadone treatment practices appear to
be making progress, but many patients are still receiving substandard
care.

JAMA. 2002;288:850-856

Author Affiliations: School of Social Service Administration and Department of Health Studies, University of Chicago (Dr D’Aunno), and Department of Health Management and Policy, School of Public Health (Dr Pollack), University of Michigan, Ann Arbor. Dr D’Aunno is now with INSEAD, Fontainebleau, France.

Corresponding Author and Reprints: Thomas D’Aunno, PhD, INSEAD, Boulevard de Constance, 77305 Fontainebleau Cedex, France (e-mail: [email protected]).

Copyright 2003 January 19, 2003

Similar Posts

  • New Methadone Regulations in the U.S.

    Admin 05/07/2021

    Press Release July 22, 1999 National Alliance of Methadone Advocates NAMA 435 Second Avenue New York, NY 10010 Email: [email protected] NAMA applauds the hard work of SAMHSA, the ONDCP, NIDA and CSAT for the release of the New Accreditation Guidelines for Methadone and LAAM Treatment. We are aware that these agencies have made tremendous efforts…

  • |

    Citation Instructions

    Admin 03/14/2023

    NAMA produces materials for education and disemination. You are free to use them in your publications, or to discribute them. These are intended only as examples. Education Series author, name of document. Education Series, Number X, date. Available from National Alliance of Methadone Advocates, 435 Second Avenue, New York, NY 10010. Policy Statement name of…

  • About Webrings

    Admin 06/24/2022

    What is a Webring? A Webring is a group of sites linked together usually around a specific topic. The purpose is to give surfers access to information about the topic that the Webring is organized around. For Example: A Webring could be organized around Little League. Some websites could belong to the various leagues and…

  • |

    Antiviral Therapy

    Admin 07/04/2021

    HCV Info Fact 9 Nov 2003 Antiviral therapy has steadily improved over the last decade. The side effect profile of interferon-based therapies has remained largely unchanged. Recent data have suggested that improved adherence to combination regimens will favorable affect sustained virologic response rates. The minimal criteria recommended by the National Institutes of Health for candidates…

  • Hepatitis C Committee

    Admin 06/24/2023

    Chair: Dr. P. Kishore, MD, MPH, CMA (Boston NAMA) Committee Members Paul Bowman, CMA  Cheri Jarvis, CMA  Hepatitis C Hepatitis is an inflammation of the liver. Although in many people the diseased liver is able to repair itself and regain function, it may progress to scarring of the liver and chronic liver disease. Hepatitis can…